Header graphic for print
LimeGreenIP News

Life Sciences and Health Care Horizons 2019 publication: IP in the mix

Innovation in the life sciences and health care industries is occurring at a dizzying pace. Five years ago, anti-PD-1 antibodies from Merck and BMS had yet to be approved, CAR-T therapies were still in small-scale clinical trials, and digital health was seen as electronic step counters and little else. Today, cures are being found for diseases and conditions once considered life threatening or permanently debilitating.

In the 2019 edition of our Life Sciences and Health Care Horizons publication, our global team identifies a number of current and evolving trends that are shaping the future of the industry. From regional coverage including Asian, European, Latin American and U.S. markets, to specific legal challenges around intellectual property and changing regulatory environments, to the prospects of future discovery driven by artificial intelligence and big data, our team reports on the extraordinary progress and opportunities in the sector around the world. IP related developments in this publication include;

  • Biosimilars patent licensing,
  • Artificial intelligence in drug design,
  • Pricing & reimbursement of medicinal products in the EU, and
  • Collaboration considerations in personal medicine.

In addition to this publication, our Life Sciences and Health Care Horizons – Global event series will span three continents and feature cutting-edge analysis, engaging panel discussions, and featured keynote speakers. Save these dates:

30 April: Boston
16 May: London
27 June: Paris
30 Oct.: Tokyo
6 Nov.: Shanghai
13 Nov.: Northern California


Helping make the world healthier: With 500 life sciences and health care lawyers across the globe, we understand the issues clients face in the countries they do business in, helping them to stay ahead of the curve – Learn more.